Comment on: “Efficacy and Safety of Saroglitazar in Patients with Cardiometabolic Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials”
- 13 January 2023
- journal article
- letter
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 43 (2) , 147-148
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Efficacy and Safety of Saroglitazar in Patients with Cardiometabolic Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsClinical Drug Investigation, 2022
- Efficacy and safety of saroglitazar for the management of dyslipidemia: A systematic review and meta-analysis of interventional studiesPLOS ONE, 2022
- Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 TrialHepatology, 2021
- Efficacy and safety of saroglitazar in managing hypertriglyceridemia in type-2 diabetes: A meta-analysisDiabetes & Metabolic Syndrome: Clinical Research & Reviews, 2020
- A Multicenter, Prospective, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared with Placebo in Type 2 Diabetes Mellitus Patients Having Hypertriglyceridemia Not Controlled with Atorvastatin Therapy (PRESS VI)Diabetes Technology & Therapeutics, 2014
- A Multicenter, Prospective, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared to Pioglitazone 45 mg in Diabetic Dyslipidemia (PRESS V)Journal of Diabetes Science and Technology, 2014
- Fenofibrate-associated nephrotoxicity: A review of current evidenceAmerican Journal of Health-System Pharmacy, 2013
- Safety Considerations with Fibrate TherapyThe American Journal of Cardiology, 2007